1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one analogs

Abstract

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

What is claimed is: 
     
         1 . A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure: 
       
         
           
           
               
               
           
         
         wherein: 
         R 1  is selected from the group consisting of an optionally substituted C 1-4  alkyl, an optionally substituted C 2-4  alkenyl, an optionally substituted C 2-4  alkynyl, an optionally substituted C 3-6  cycloalkyl and an optionally substituted C 3-6  cycloalkyl(C 1-4  alkyl), wherein when substituted, the C 1-4  alkyl, the C 2-4  alkenyl and the C 2-4  alkynyl are independently substituted with one or more substituents selected from the group consisting of halogen, C 1-4  alkoxy, C 1-4  haloalkyl, C 1-4  haloalkoxy, cyano, amino, mono-C 1-4  alkyl amine and di-C 1-4  alkyl amine, and wherein the ring(s) of the C 3-6  cycloalkyl and the C 3-6  cycloalkyl(C 1-4  alkyl) are independently substituted with one or more substituents selected from the group consisting of halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, C 1-4  haloalkoxy, cyano, amino, mono-C 1-4  alkyl amine and di-C 1-4  alkyl amine; 
         R 2  is an optionally substituted aryl or an optionally substituted heteroaryl, wherein when the aryl or the heteroaryl are substituted, the aryl and the heteroaryl are independently substituted with one or more substituents selected from the group consisting of an unsubstituted C 1-4  alkyl and 
       
       
         
           
           
               
               
           
         
         R 3  is hydrogen or an unsubstituted C 1-4  alkyl; 
         A 1  is CR 6A  or N; 
         A 2  is CR 6B  or N; 
         Z 1  is a single bond, —C(═O)— or an optionally substituted C 1-6  alkylene group, wherein one or two more methylene groups constituting the optionally substituted C 1-6  alkylene group are independently optionally replaced by an oxygen atom or carbonyl group, and wherein when the C 1-6  alkylene group is substituted, one or more methylene group are independently substituted with an unsubstituted C 1-6  alkyl group; 
         Z 2  is N or C, and when Z 2  is N, then R 4c  is absent; 
         R 4a  and R 4b  are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, an unsubstituted C 1-6  alkyl, an unsubstituted hydroxy(C 1-6  alkyl), an unsubstituted alkoxy(C 1-6  alkyl), an unsubstituted C 2-7  acyl, an unsubstituted —C-carboxy having 2-7 carbons, an unsubstituted —C-amido and an unsubstituted C 1-7  alkylsulfonyl; or 
         R 4a  and R 4b  together form an optionally substituted C 1-6  alkylene, wherein one or two more methylene groups constituting the C 1-6  alkylene group are independently optionally replaced by an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group or —(NR 5 )—, and wherein when the C 1-6  alkylene group is substituted, one or more methylene group are independently substituted with a substituent selected from the group consisting of halogen and an unsubstituted C 1-6  alkyl; or 
         R 4a  and R 4b  together with Z 2  form an unsubstituted monocyclic C 3-6  cycloalkyl and an unsubstituted 4-, 5-, or 6-membered heterocyclyl; 
         R 4c  is selected from the group consisting of halogen, hydroxy, an unsubstituted C 1-6  alkyl and an unsubstituted hydroxy(C 1-6  alkyl); 
         R 5  is hydrogen, an unsubstituted C 1-6  alkyl or an unsubstituted C 1-6  haloalkyl; 
         R 6A  and R 6B  are independently hydrogen, halogen or an unsubstituted C 1-4  alkyl; and 
         Ring B is an optionally substituted monocyclic C 5-7  cycloalkyl, an optionally substituted 5-7 membered monocyclic heterocyclyl or an optionally substituted 7-10 membered bicyclic heterocyclyl, wherein when Ring B is substituted, Ring B is substituted with one or more substituents selected from the group consisting of halogen, an optionally substituted C 1-6  alkyl, an optionally substituted C 1-6  haloalkyl, an optionally substituted C 3-6  cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C 1-6  alkyl), an optionally substituted heteroaryl(C 1-6  alkyl), an optionally substituted heterocyclyl(C 1-6  alkyl), an optionally substituted acyl, an optionally substituted -hydroxy(C 1-6  alkyl), an optionally substituted —C-amido, an optionally substituted —C-amido(C 1-6  alkyl), an optionally substituted —N-amido, an optionally substituted —N-amido(C 1-6  alkyl), an optionally substituted mono-substituted amine, an optionally substituted di-substituted amine, an optionally substituted mono-substituted amine(C 1-6  alkyl), an optionally substituted di-substituted amine(C 1-6  alkyl) and an optionally substituted sulfonyl. 
       
     
     
         2 . The compound of  claim 1 , wherein the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt of any of the foregoing. 
       
     
     
         3 . The compound of  claim 1 , wherein the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt of any of the foregoing. 
     
     
         4 . A pharmaceutical composition comprising an effective amount of the compound of  claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof. 
     
     
         5 . A method for ameliorating or treating a cancer comprising administering an effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, to a subject having the cancer, wherein the cancer is selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma. 
     
     
         6 . A method for inhibiting replication of a malignant growth or a tumor comprising contacting the growth or the tumor with an effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the malignant growth or tumor is due to a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma. 
     
     
         7 . A method for ameliorating or treating a cancer comprising contacting a malignant growth or a tumor with an effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, wherein the malignant growth or tumor is due to a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma. 
     
     
         8 . A method for inhibiting the activity of WEE1 comprising providing an effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, to a cancer cell, wherein the cancer cell is from a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma. 
     
     
         9 . A method for inhibiting the activity of WEE1 comprising providing an effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, to a subject having a cancer or a cancer cell, wherein the cancer is selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma.